Keymed Biosciences Inc. (2162.HK)

34.950 +1.300 (+3.86%) At close: 04:09PM HKT

Keymed Biosciences Inc.

Building D2
No. 18 BioTown Middle Road Tianfu International BioTown Shuangliu District
Chengdu 610219
China
86 28 8861 0620
https://www.keymedbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 897

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Bo Chen	Executive Chairman & CEO	4.44M	N/A	1975
Dr. Gang Xu	Senior VP & Executive Director	1.49M	N/A	1975
Dr. Changyun Wang	Senior VP & Executive Director	2.44M	N/A	1966
Mr. Qi Chen	Senior VP & Non Executive Director	690.87k	N/A	1975
Mr. Yanrong Zhang	CFO & Joint Company Secretary	N/A	N/A	1989
Dr. Qian Jia	Senior Vice President	N/A	N/A	1966
Ms. Pak Yu Tam A.C.I.S., A.C.S.	Joint Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.

Corporate governance

Keymed Biosciences Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.